Peginterferon alfa-2b

It is used to treat skin cancer .

It is used to treat skin cancer .

peginterferon alfa-2b is contraindicated in conditions like Autoimmune hepatitis,Hypersensitivity to the drug.

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat. Signs of thyroid problems like change in weight; feeling nervous, excitable, restless, or weak; hair thinning; depression ; neck swelling; not able to focus; trouble with heat or cold; menstrual changes; shakiness; or sweating. Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit. Weakness on 1 side of the body, trouble speaking or thinking, change in balance, drooping on one side of the face, or blurred eyesight. Chest pain or pressure. Fast or abnormal heartbeat. Very bad dizziness or passing out. Change in look of teeth or gums. A burning, numbness, or tingling feeling that is not normal. This medicine may cause eye problems that may lead to loss of eyesight or blindness. Tell your doctor if you have or have ever had eye problems. Call your doctor right away if you have any changes in eyesight. Some people have had lung problems with peginterferon alfa-2b (sylatron). Sometimes, this has been deadly. Call your doctor right away if you have signs of lung problems like shortness of breath or other trouble breathing, cough that is new or worse, or fever. Severe bowel problems (colitis) have happened within 12 weeks of treatment with alpha interferons like peginterferon alfa-2b (sylatron). Sometimes, this could be deadly. Call your doctor right away if you have severe stomach pain, bloody diarrhea, throwing up blood, or throw up that looks like coffee grounds.

Safety and efficacy in pediatrics less than 3 years old have not been established. Neuropsychiatric, cardiac, pulmonary, GI, and systemic (flu-like) adverse reactions may be more severe in geriatric patients. Safety and efficacy have not been estacblished in HIV or HBV co-infected and organ transplant patients. It is contraindicated in patients with creatinine clearance less than 50 mL/min. It is also contraindicated in pregnant women and patients with Hemoglobinopathies when taken in combination with ribavirin. Birth defects and fetal death with ribavirin: Patients must have a negative pregnancy test prior to therapy, use at least 2 forms of contraception, and undergo monthly pregnancy tests. Patients exhibiting the following conditions should be closely monitored and may require dose reduction or discontinuation of therapy: Hemolytic anemia with ribavirin. Neuropsychiatric events. History of significant or unstable cardiac isease. Hypothyroidism, hyperthyroidism, hyperglycemia, diabetes mellitus that cannot be effectively treated by medication. New or worsening ophthalmologic disorders. Ischemic and hemorrhagic cerebrovascular events. Severe decreases in neutrophil or platelet counts. History of autoimmune disorders. Pancreatitis and ulcerative or hemorrhagic/ischemic colitis and pancreatitis. Pulmonary infiltrates or pulmonary function impairment. Child-Pugh score greater than 6 (class B and C). Increased creatinine levels in patients with renal insufficiency. Serious, acute hypersensitivity reactions and cutaneous eruptions. Dental/periodontal disorders reported with combination therapy. Hypertriglyceridemia may result in pancreatitis (e.g., triglycerides greater than 1000 mg/dL). Weight loss and growth inhibition reported with combination therapy in pediatric patients. Peripheral neuropathy when used in combination with telbivudine.

Drug should not be given to Pregnant Mothers, Cardiac / Hypertensive Patients, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

1 to 1 mcg/kg/week (1 (1)) As recommended. Sc — Dose reduction or discontinuation is required in case of depression, haemtological and renal side effects. For patients with a history of stable cardiac disease receiving Pegnterferon alfa 2b in combination with ribavirin, dose should be reduced by half and the ribavirin dose by 200mg/day if a 2g/dL decrease in hemoglobin is observed during any 4 week period. Both Peginterferon alpha 2b and ribavirin should be permanently discontinued if patients have hemoglobin levels 1.5 to 1.5 mcg/kg/week (1.5 (1.5)) As recommended. Sc — when it is used in combination with ribavirin.

60 to 0 mcg/m2/week (30 (30)) As recommended. Sc — This is the dose when given in combination with ribavirin

No neonatal dosage information is recorded for this medicine yet.

No data regarding the interactions of peginterferon alfa-2b was found.

Injection Use within 24 hours if refrigerated.